Aliases:This biomarker is also known as:
- Tumor-amplified and overexpressed sequence 2,
- anoctamin 1, calcium activated chloride channel,
- oral cancer overexpressed 2,
- discovered on gastrointestinal stromal tumors protein 1,
- Transmembrane protein 16A,
- Discovered on gastrointestinal stromal tumors protein 1,
- transmembrane protein 16A (eight membrane-spanning domains),
- tumor-amplified and overexpressed sequence 2,
- Oral cancer overexpressed protein 2,
- transmembrane protein 16A,
ANO1, or anoctamin-1, is a calcium-activated chloride channel gene overexpressed in many tumors. ANO1 is ubiquitously expressed in epithelia and is thought to be important in epithelial fluid transport.
There are no datasets associated with this biomarker.
The following organs have data associated with this biomarker…
|QA State:||Under Review|
ANO1 is located within the 11q13 amplicon, one of the most frequently amplified chromosomal regions in human cancer. ANO1 is amplified and highly expressed in breast cancer cell lines and primary tumors.
ANO1 was one of numerous potential early detection biomarkers specific to triple-negative breast cancer in multiple pathways identified.
- Discovery and preliminary confirmation of novel early detection biomarkers for triple-negative breast cancer using preclinical plasma samples from the Women's Health Initiative observational study.
- Development and validation of sandwich ELISA microarrays with minimal assay interference.
- Plasma biomarker profiles differ depending on breast cancer subtype but RANTES is consistently increased.
- Calcium-activated chloride channel ANO1 promotes breast cancer progression by activating EGFR and CAMK signaling.